Navigation Links
OrbusNeich File Patent Infringement Lawsuit Against Boston Scientific in Ireland
Date:3/8/2013

FORT LAUDERDALE, Fla., March 8, 2013 /PRNewswire/ -- OrbusNeich Medical Inc. and its subsidiary, Orbus International B.V., (collectively, "OrbusNeich") today announced that they have commenced a patent infringement lawsuit in Ireland against Boston Scientific Corporation (NYSE: BSX) and two of its Irish subsidiaries (collectively, "Boston Scientific").

The lawsuit alleges that Boston Scientific are infringing two European patents covering certain novel stent designs.  The two patents, held by OrbusNeich, are designated EP 2 311 412 and EP 1 341 482.  OrbusNeich allege that the patents are infringed by a number of Boston Scientific's coronary stent systems, including the "PROMUS Element™", "PROMUS Element Plus™", "OMEGA™", "TAXUS™", "SYNERGY™", and "Promus PREMIER™" lines of stents.

OrbusNeich are seeking damages for the infringement and an injunction prohibiting Boston Scientific from manufacturing, offering for sale, marketing or stocking products that infringe the patents in Ireland.

Al Novak , Chairman and Chief Executive Officer of OrbusNeich, said, "The lawsuit in Ireland is a continuation of our efforts to protect and enforce our intellectual property rights. We intend to vigorously pursue these efforts to prevent unlawful competitive practices and protect our unique technologies throughout the world."

On February 20, 2013, OrbusNeich commenced patent infringement actions in Germany and the Netherlands against Boston Scientific and its distribution affiliates in those countries.  

On February 11, 2013, OrbusNeich received a favorable ruling from the European Patent Office (EPO) in connection with EP 1 341 482, one of the two patents asserted against Boston Scientific in these lawsuits. The EPO upheld the validity of claim 1 of the '482 patent, as amended, over an opposition filed by Boston Scientific and Terumo Kabushiki Kaisha.  The EPO found that claim 1 of the '482 patent met all requirements of the European Patent Convention, and that the stents covered by the claim were novel and inventive over the prior art.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.


'/>"/>
SOURCE OrbusNeich
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
2. OrbusNeich Announces Favorable Ruling From the European Patent Office
3. OrbusNeich Files Patent Infringement Actions Against Boston Scientific in Germany and the Netherlands
4. Essential Medical Dismisses Patent Case against Masimo and Cercacor
5. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
6. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
7. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
8. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
9. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
10. Broad Patent Protection Granted for iBio Immunomodulator
11. Bio-AMD, Inc.; Patent Application for Cartridge Test Cap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... With the onset of long work hours and ... fractures due to falls at work and at home will only continue to grow unless ... are not following proper safety procedures, a fall at work or home can lead to ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... technology makes it possible to see through objects, has announced the winners of ... consumer apps with its fully programmable, Raspberry Pi-enabled 3D sensor, Walabot . ...
(Date:6/28/2017)... ... , ... As we celebrate our nation’s independence, many Americans will gather around ... time to celebrate National Hot Dog Month. The National Hot Dog and Sausage ... 4th alone and while they enjoy many different kinds of hot dogs, research commissioned ...
(Date:6/28/2017)... ... 2017 , ... Quorum Health announced that Robert A. Vento has been appointed ... Maher was promoted to COO of QHR. , A national search was ... and CEO in December 2016. , “I’m pleased to announce these ...
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
Breaking Medicine News(10 mins):